{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T01:05:19Z","timestamp":1786323919490,"version":"build-2736575974"},"reference-count":66,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","onlinecjc.ca","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Canadian Journal of Cardiology"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.cjca.2019.11.032","type":"journal-article","created":{"date-parts":[[2019,12,9]],"date-time":"2019-12-09T12:10:56Z","timestamp":1575893456000},"page":"384-395","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["The Challenges in Chemotherapy and Stem Cell Transplantation for Light-Chain Amyloidosis"],"prefix":"10.1016","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2210-2174","authenticated-orcid":false,"given":"Eli","family":"Muchtar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha","family":"Grogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cjca.2019.11.032_bib1","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41572-018-0034-3","article-title":"Systemic immunoglobulin light chain amyloidosis","volume":"4","author":"Merlini","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.cjca.2019.11.032_bib2","first-page":"472","article-title":"A\u00a0Modern primer on light chain amyloidosis in 592 patients with mass spectrometry-verified typing","volume":"94","author":"Muchtar","year":"2019","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.cjca.2019.11.032_bib3","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1007\/s12325-015-0250-0","article-title":"Light chain amyloidosis: patient experience survey from the Amyloidosis Research Consortium","volume":"32","author":"Lousada","year":"2015","journal-title":"Adv Ther"},{"key":"10.1016\/j.cjca.2019.11.032_bib4","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1182\/blood-2016-11-751628","article-title":"Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death","volume":"129","author":"Muchtar","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.cjca.2019.11.032_bib5","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.mayocp.2015.06.009","article-title":"Treatment of immunoglobulin light chain amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement","volume":"90","author":"Dispenzieri","year":"2015","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.cjca.2019.11.032_bib6","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1111\/bjh.16096","article-title":"Ten-year survivors in AL amyloidosis: characteristics and treatment pattern","volume":"187","author":"Muchtar","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.cjca.2019.11.032_bib7","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/bjh.16094","article-title":"Lessons in long term survival from AL amyloidosis","volume":"187","author":"Sloan","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.cjca.2019.11.032_bib8","doi-asserted-by":"crossref","first-page":"3751","DOI":"10.1200\/JCO.2004.03.029","article-title":"Serum cardiac troponins and N-terminal pro\u2013brain natriuretic peptide: a staging system for primary systemic amyloidosis","volume":"22","author":"Dispenzieri","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cjca.2019.11.032_bib9","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1200\/JCO.2011.38.5724","article-title":"Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements","volume":"30","author":"Kumar","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cjca.2019.11.032_bib10","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1038\/s41375-018-0370-z","article-title":"Comparative analysis of staging systems in AL amyloidosis","volume":"33","author":"Muchtar","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.cjca.2019.11.032_bib11","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.1200\/JCO.2015.62.4015","article-title":"Improved outcomes after autologous hematopoietic cell transplantation for light chain amyloidosis: a Center for International Blood and Marrow Transplant Research study","volume":"33","author":"d\u2019Souza","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cjca.2019.11.032_bib12","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1200\/JCO.2017.76.9554","article-title":"Stem cell transplantation for light chain amyloidosis: decreased early mortality over time","volume":"36","author":"Sidiqi","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cjca.2019.11.032_bib13","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1093\/ndt\/gfv328","article-title":"The impact of dialysis on the survival of patients with immunoglobulin light chain (AL) amyloidosis undergoing autologous stem cell transplantation","volume":"31","author":"Leung","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.cjca.2019.11.032_bib14","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1182\/blood-2011-07-370031","article-title":"High-dose melphalan and peripheral blood stem cell transplantation for light-chain amyloidosis with cardiac involvement","volume":"119","author":"Madan","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.cjca.2019.11.032_bib15","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/j.hoc.2014.08.013","article-title":"High dose melphalan and autologous peripheral blood stem cell transplantation in AL amyloidosis","volume":"28","author":"Sanchorawala","year":"2014","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.cjca.2019.11.032_bib16","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1038\/bmt.2014.117","article-title":"Plerixafor and G-CSF for autologous stem cell mobilization in AL amyloidosis","volume":"49","author":"Kaul","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.cjca.2019.11.032_bib17","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/bmt.2013.192","article-title":"Safety and efficacy of high-dose melphalan and auto-SCT in patients with AL amyloidosis and cardiac involvement","volume":"49","author":"Girnius","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.cjca.2019.11.032_bib18","first-page":"455","article-title":"Prognostic significance of holter monitor findings in patients with light chain amyloidosis","volume":"94","author":"Sidana","year":"2019","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.cjca.2019.11.032_bib19","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s10741-014-9464-5","article-title":"Natural history and therapy of AL cardiac amyloidosis","volume":"20","author":"Grogan","year":"2015","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.cjca.2019.11.032_bib20","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.hrthm.2007.10.016","article-title":"Prophylactic implantation of cardioverter-defibrillator in patients with severe cardiac amyloidosis and high risk for sudden cardiac death","volume":"5","author":"Kristen","year":"2008","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.cjca.2019.11.032_bib21","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1111\/jce.12123","article-title":"Implantable cardioverter defibrillators in patients with cardiac amyloidosis","volume":"24","author":"Lin","year":"2013","journal-title":"J\u00a0Cardiovasc Electrophysiol"},{"key":"10.1016\/j.cjca.2019.11.032_bib22","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/bjh.14747","article-title":"Role of implantable intracardiac defibrillators in patients with cardiac immunoglobulin light chain amyloidosis","volume":"182","author":"Rezk","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.cjca.2019.11.032_bib23","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.hrthm.2013.10.026","article-title":"Implantable cardioverter-defibrillator placement in patients with cardiac amyloidosis","volume":"11","author":"Varr","year":"2014","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.cjca.2019.11.032_bib24","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1038\/s41409-019-0440-5","article-title":"High-dose melphalan and autologous peripheral blood stem cell transplantation in patients with AL amyloidosis and cardiac defibrillators","volume":"54","author":"Phull","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.cjca.2019.11.032_bib25","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.amjcard.2004.10.028","article-title":"Electrocardiographic findings in primary systemic amyloidosis and biopsy-proven cardiac involvement","volume":"95","author":"Murtagh","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cjca.2019.11.032_bib26","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1212\/WNL.0b013e3181d55f4d","article-title":"Stem cell transplantation in patients with autonomic neuropathy due to primary (AL) amyloidosis","volume":"74","author":"Dingli","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.cjca.2019.11.032_bib27","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1080\/13506129.2018.1449744","article-title":"Digoxin use in systemic light-chain (AL) amyloidosis: contra-indicated or cautious use?","volume":"25","author":"Muchtar","year":"2018","journal-title":"Amyloid"},{"key":"10.1016\/j.cjca.2019.11.032_bib28","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1111\/joim.12617","article-title":"Prevalence and predictors of thyroid functional abnormalities in newly diagnosed AL amyloidosis","volume":"281","author":"Muchtar","year":"2017","journal-title":"J\u00a0Intern Med"},{"key":"10.1016\/j.cjca.2019.11.032_bib29","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1111\/jce.13046","article-title":"Catheter ablation for atrial arrhythmias in patients with cardiac amyloidosis","volume":"27","author":"Tan","year":"2016","journal-title":"J\u00a0Cardiovasc Electrophysiol"},{"key":"10.1016\/j.cjca.2019.11.032_bib30","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.jacc.2018.10.079","article-title":"Direct current cardioversion of atrial arrhythmias in adults with cardiac amyloidosis","volume":"73","author":"El-Am","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2019.11.032_bib31","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/bmt.2015.21","article-title":"High-dose therapy with auto-SCT is feasible in high-risk cardiac amyloidosis","volume":"50","author":"Kongtim","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.cjca.2019.11.032_bib32","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/j.1600-0609.2012.01815.x","article-title":"Evaluation of pretransplant factors predicting cardiac dysfunction following high-dose melphalan conditioning and autologous peripheral blood stem cell transplantation","volume":"89","author":"Bleeker","year":"2012","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.cjca.2019.11.032_bib33","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/j.jacc.2016.06.053","article-title":"AL (light-chain) cardiac amyloidosis: a review of diagnosis and therapy","volume":"68","author":"Falk","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2019.11.032_bib34","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1093\/eurheartj\/ehu506","article-title":"A\u00a0study of implanted cardiac rhythm recorders in advanced cardiac AL amyloidosis","volume":"36","author":"Sayed","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2019.11.032_bib35","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.currproblcancer.2017.03.001","article-title":"Stem cell transplantation for immunoglobulin light chain amyloidosis","volume":"41","author":"Sher","year":"2017","journal-title":"Curr Probl Cancer"},{"key":"10.1016\/j.cjca.2019.11.032_bib36","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/s41375-018-0262-2","article-title":"Daratumumab-based therapy in patients with heavily-pretreated AL amyloidosis","volume":"33","author":"Abeykoon","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.cjca.2019.11.032_bib37","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1182\/blood-2016-08-730978","article-title":"The amyloidogenic light chain is a stressor that sensitizes plasma cells to proteasome inhibitor toxicity","volume":"129","author":"Oliva","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.cjca.2019.11.032_bib38","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1200\/JCO.19.00231","article-title":"Prospective study of cardiac events during proteasome inhibitor therapy for relapsed multiple myeloma","volume":"37","author":"Cornell","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cjca.2019.11.032_bib39","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1093\/qjmed\/hcr105","article-title":"Bortezomib in a phase 1 trial for patients with relapsed AL amyloidosis: cardiac responses and overall effects","volume":"104","author":"Dubrey","year":"2011","journal-title":"QJM"},{"key":"10.1016\/j.cjca.2019.11.032_bib40","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1182\/blood-2011-02-334227","article-title":"Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1\/2 study","volume":"118","author":"Reece","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.cjca.2019.11.032_bib41","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1161\/CIRCULATIONAHA.109.904557","article-title":"Ubiquitin proteasome dysfunction in human hypertrophic and dilated cardiomyopathies","volume":"121","author":"Predmore","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2019.11.032_bib42","doi-asserted-by":"crossref","first-page":"4051","DOI":"10.1113\/JP273607","article-title":"Proteasome dysfunction in cardiomyopathies","volume":"595","author":"Gilda","year":"2017","journal-title":"J\u00a0Physiol"},{"key":"10.1016\/j.cjca.2019.11.032_bib43","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1111\/ejh.12749","article-title":"A\u00a0practical review on carfilzomib in multiple myeloma","volume":"96","author":"Muchtar","year":"2016","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.cjca.2019.11.032_bib44","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1470-2045(15)00464-7","article-title":"Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study","volume":"17","author":"Dimopoulos","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cjca.2019.11.032_bib45","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1182\/blood.V128.22.645.645","article-title":"Safety and efficacy of carfilzomib (CFZ) in previously-treated systemic light-chain (AL) amyloidosis","volume":"128","author":"Cohen","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.cjca.2019.11.032_bib46","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1182\/blood-2017-03-771220","article-title":"A\u00a0phase 1\/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis","volume":"130","author":"Sanchorawala","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.cjca.2019.11.032_bib47","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1002\/ajh.24608","article-title":"Ixazomib cardiotoxicity: a possible class effect of proteasome inhibitors","volume":"92","author":"Jouni","year":"2017","journal-title":"Am J Hematol"},{"issue":"Suppl 1","key":"10.1016\/j.cjca.2019.11.032_bib48","article-title":"Primary results from the phase 3 TOURMALINE-AL1 trial of ixazomib-dexamethasone versus physician\u2019s choice of therapy in patients (Pts) with relapsed\/refractory primary systemic AL amyloidosis (RRAL)","volume":"134","author":"Dispenzieri","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.cjca.2019.11.032_bib49","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.critrevonc.2016.01.004","article-title":"Immunomodulatory drugs in AL amyloidosis","volume":"99","author":"Jelinek","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.cjca.2019.11.032_bib50","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1093\/ndt\/gfq482","article-title":"Kidney dysfunction during lenalidomide treatment for AL amyloidosis","volume":"26","author":"Specter","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.cjca.2019.11.032_bib51","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1002\/ajh.21822","article-title":"Discordance between serum cardiac biomarker and immunoglobulin-free light-chain response in patients with immunoglobulin light-chain amyloidosis treated with immune modulatory drugs","volume":"85","author":"Dispenzieri","year":"2010","journal-title":"Am J Hematol"},{"key":"10.1016\/j.cjca.2019.11.032_bib52","doi-asserted-by":"crossref","first-page":"5397","DOI":"10.1182\/blood-2012-02-413161","article-title":"Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis","volume":"119","author":"Dispenzieri","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.cjca.2019.11.032_bib53","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1182\/blood-2016-12-756528","article-title":"A\u00a0phase II trial of pomalidomide and dexamethasone rescue treatment in patients with AL amyloidosis","volume":"129","author":"Palladini","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.cjca.2019.11.032_bib54","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1182\/blood-2016-04-710822","article-title":"Pomalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 1 and 2 trial","volume":"128","author":"Sanchorawala","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.cjca.2019.11.032_bib55","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1182\/blood-2017-01-763599","article-title":"Daratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosis","volume":"130","author":"Kaufman","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.cjca.2019.11.032_bib56","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/bjh.15455","article-title":"Daratumumab proves safe and highly effective in AL amyloidosis","volume":"185","author":"Khouri","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.cjca.2019.11.032_bib57","first-page":"508","article-title":"A\u00a0prospective phase II of daratumumab in previously-treated systemic light-chain (AL) amyloidosis","volume":"130","author":"Roussel","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.cjca.2019.11.032_bib58","first-page":"507","article-title":"Safety and tolerability of daratumumab in patients with relapsed light chain (AL) amyloidosis: preliminary results of a phase II study","volume":"130","author":"Sanchorawala","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.cjca.2019.11.032_bib59","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1111\/bjh.16282","article-title":"Daratumumab is effective in the relapsed or refractory systemic light-chain amyloidosis but associated with high infection burden in a frail real-life population","volume":"188","author":"Van de Wyngaert","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1016\/j.cjca.2019.11.032_bib60","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1200\/JCO.2011.37.7614","article-title":"New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes","volume":"30","author":"Palladini","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cjca.2019.11.032_bib61","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/s41375-018-0258-y","article-title":"Optimizing deep response assessment for AL amyloidosis using involved free light chain level at end of therapy: failure of the serum free light chain ratio","volume":"33","author":"Muchtar","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.cjca.2019.11.032_bib62","doi-asserted-by":"crossref","first-page":"3426","DOI":"10.1182\/blood-2010-05-286567","article-title":"The combination of high-sensitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy best predicts survival in AL amyloidosis","volume":"116","author":"Palladini","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.cjca.2019.11.032_bib63","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1038\/s41375-018-0060-x","article-title":"Depth of organ response in AL amyloidosis is associated with improved survival: grading the organ response criteria","volume":"32","author":"Muchtar","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.cjca.2019.11.032_bib64","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/bjh.14585","article-title":"The six-minute walk test is a valuable measure of functional change following chemotherapy for AL (light-chain) cardiac amyloidosis","volume":"177","author":"Decker","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1016\/j.cjca.2019.11.032_bib65","first-page":"509","article-title":"Final analysis of the phase 1a\/b study of chimeric fibril-reactive monoclonal antibody 11-1F4 in patients with relapsed or refractory AL amyloidosis","volume":"130","author":"Edwards","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.cjca.2019.11.032_bib66","doi-asserted-by":"crossref","first-page":"380","DOI":"10.5500\/wjt.v6.i2.380","article-title":"Long term outcomes of cardiac transplant for immunoglobulin light chain amyloidosis: the Mayo Clinic experience","volume":"6","author":"Grogan","year":"2016","journal-title":"World J Transplant"}],"container-title":["Canadian Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X19315065?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X19315065?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:42:01Z","timestamp":1760107321000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0828282X19315065"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":66,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["S0828282X19315065"],"URL":"https:\/\/doi.org\/10.1016\/j.cjca.2019.11.032","relation":{},"ISSN":["0828-282X"],"issn-type":[{"value":"0828-282X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Challenges in Chemotherapy and Stem Cell Transplantation for Light-Chain Amyloidosis","name":"articletitle","label":"Article Title"},{"value":"Canadian Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cjca.2019.11.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}